NRX Pharmaceuticals, Inc. — Form 10-Q
Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
NRX Defense Systems, Inc. (subsidiary of NRx Pharmaceuticals) signed an 18-month DARPA 'other transaction' agreement (HR0011-26-3-E138) for $11,177,757 total value, with $6,681,753 currently obligated. The agreement funds a 240-patient randomized controlled trial combining ultra-accelerated transcranial magnetic stimulation (uaTMS) with NRX-101 (D-cycloserine + lurasidone) to treat treatment-resistant depression in military personnel. Milestone-based payments via pre-established schedule; NRX retains patent rights with DARPA receiving nonexclusive license; agreement commenced upon final signature (filed November 2026).
Why this rating
DARPA funding of $6.7M obligated (11.7% of company's $57.4M market cap) for pivotal trial is meaningful and advances FDA approval path for core asset NRX-101, but subject to trial success and milestone achievement.
Tradability signal
NO TRADE
No trade: positive news with only +0.7% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.26% over 4 hrs, n=543). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $2.14 ▲ 0.01% | at our read · unknown $2.14 | +10 min · unknown $2.24 ▲ 4.91% | +30 min · unknown $2.31 ▲ 8.23% | +1 hr · unknown $2.46 ▲ 15.01% | +4 hrs · unknown $2.34 ▲ 9.40% |
The stock had already moved -0.01% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.